ASX Announcements


 
    Results of 2018 AGM  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to Shareholders  
 
    Removal from Official List  
 
    Appendix 4C - Quarter Ended 31 March 2018  
 
    Initial Director's Interest Notice  
 
    Director Appointment  
 
    Half Yearly Report and Accounts - 31 December 2017  
 
    Appendix 4C - Quarter Ended 31 December 2017  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 4C - Quarter Ended 30 September 2017  
 
    Appendix 4G - Corporate Governance  
 
    Annual Report to shareholders  
 
    Preliminary Final Report  
 
    Appendix 4C - Quarter Ended 31 March 2017  
 
    Half Yearly Report and Accounts - 31 December 2016  
 
    Appendix 4C - Quarter Ended 31 December 2016  
 
    Auditor Appointment / Resignation  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report 2016  
 
    Appendix 4C - Quarter Ended 30 September 2016  
 
    Initial Director's Interest Notice- J Rainbow  
 
    Initial Director's Interest Notice- T Heesh  
 
    Final Director's Interest Notice- B Hancox  
 
    Final Director's Interest Notice- R Treagus  
 
    Change in Board Composition  
 
    Suspension from Official Quotation - Annual Listing Fees  
 
    Change of Registered Office & Company Secretary  
 
    Appendix 4G - Corporate Governance Statement  
 
    Preliminary Final Report - 30 June 2016  
 
    Appendix 4C - Quarter Ended 30 June 2016  
 
    Response to ASX Query  
 
    Change of Director's Interest Notice - Bruce Hancox  
 
    Results of 2015 Annual General Meeting  
 
    Chairman's Address to Shareholders  
 
    Appendix 4C - Quarter Ended 31 March 2016  
 
    Notice of 2015 Annual General Meeting/Proxy Form  
 
    Half Yearly Report and Accounts - 31 December 2015  
 
    Appendix 4C - Quarter Ended 31 December 2015  
 
    Appendix 4C - Quarter Ended 30 September 2015  
 
    Appendix 4G - Corporate Governance Statement  
 
    Annual report and full year financial results - 30 June 2015  
 
    Appendix 4C - Quarter Ended 30 June 2015  
 
    Letter to Shareholders  
 
    Letter to Shareholders  
 
    Letter to Shareholders  
 
    Letter to Shareholders /Notice of meeting of Creditors  
 
    Letter to Shareholders  
 
    Letter to Shareholders  
 
    ASX Announcement  
 
    Letter to Shareholders  
 
    Letter to Shareholders  
 
    ASX Announcement  
 
    Response to ASX Price Query  
 
    Appointment of Voluntary Administrator  
 
    Suspension from Official Quotation  
 
    Appendix 4C - Quarter Ended 31 March 2015  
 
    Response to ASX Price Query  
 
    Change in substantial holding  
 
    Half Yearly Report and Accounts - 31 December 2014  
 
    Appendix 4C - Quarter Ended 31 December 2014  
 
    Results of 2014 Annual General Meeting  
 
    Chairman's Address to Shareholders  
 
    Appendix 4C - Quarter Ended 30 September 2014  
 
    QRxPharma Annual Report - 30 June 2014  
 
    Notice of the 2014 Annual General Meeting  
 
    2014 Annual General Meeting - Wednesday, 29 October 2014  
 
    Preliminary Final Report - 30 June 2014  
 
    QRxPharma Halts Moxduo Development  
 
    QRxPharma General Shareholder Update  
 
    Appendix 4C - Quarter Ended 30 June 2014  
 
    Initial Director's Interest Notice - Richard Treagus  
 
    Initial Director's Interest Notice - Bruce Hancox  
 
    Final Director's Interest Notice - Peter Campbell  
 
    Final Director's Interest Notice - Michael Quinn  
 
    Final Director's Interest Notice - Gary Pace  
 
    Final Director's Interest Notice - Peter Farrell  
 
    Feedback on End-of-Review Meeting with the FDA on Moxduo  
 
    Results of 9 July 2014 General Meeting  
 
    Board Resignations and General Meeting Chairman's Address  
 
    Letter to Shareholders from Chairman of General Meeting  
 
    Change of Director's Interest Notice - Michael Quinn  
 
    FDA Confirms Review Meeting Regarding MOXDUO NDA  
 
    Notice of General Meeting/Proxy Form - 9 July 2014  
 
    Change of Director's Interest Notice - Peter Campbell  
 
    Change of Director's Interest Notice - Michael Quinn  
 
    Change of Director's Interest Notice - Peter Farrell  
 
    Complete Response Letter from FDA regarding Moxduo NDA  
 
    Moxduo Status Overview May 2014  
 
    Notice under Sections 249D & 203D of the Corporations Act  
 
    Final Director's Interest Notice - John Holaday  
 
    Change of Director's Interest Notice - Gary Pace  
 
    Change of Director's Interest Notice - John Holaday  
 
    Appendix 3B - Option Issue  
 
    CEO Remuneration Package and Key Terms  
 
    Reissue - Dr. Edward Rudnic Appointed CEO of QRxPharma  
 
    Dr. Edward Rudnic Appointed CEO of QRxPharma  
 
    Appendix 4C - Quarter Ended 31 March 2014  
 
    CEO Discusses Moxduo Advisory Committee Meeting Outcomee  
 
    QRxPharma Issues Statement On Moxduo Advisory Committee  
 
    FDA Webcast Details For Moxduo Advisory Committee Meeting  
 
    Moxduo Post Advisory Committee Meeting Investor Call Details  
 
    Trading Halt  
 
    FDA sets 22 April 2014 for Moxduo Advisory Committee Meeting  
 
    Appendix 3B - Exercise of Stock Options  
 
    ASX / Media Release - Results Half Year 31 December 2013  
 
    Half Yearly Report and Accounts - 31 December 2013  
 
    Appendix 3B - Exercise of Stock Options  
 
    Appendix 4C - Quarter Ended 31 December 2013  
 
    Details of Company Address  
 
    Holaday - Cease to be substantial holder  
 
    Change of Director's Interest Notice - Peter Campbell  
 
    QRxPharma Despatches SPP Holding Statements  
 
    Appendix 3B - Share Purchase Plan  
 
    $4.1 Million SPP Completes A$11.6 Million Capital Raising  
 
    25 May 2014 as New PDUFA Date for MOXDUO NDA  
 
    MOXDUO License with TEVA for Commercialisation in Israel  
 
    QRxPharma Refiles MOXDUO New Drug Application with the FDA  
 
    Change in substantial holding  
 
    Appendix 3B - Option Issue  
 
    Notification Section 708A(5)(e) Corporations Act 2001 (Cth)  
 
    Appendix 3B - Placement Issue announced 13 November 2013  
 
    Share Purchase Plan Opens 19 November 2013  
 
    Placement and SPP - ASX Listing Rule 3.10.3 Notice  
 
    Results of 2013 Annual General Meeting  
 
    Chairman and Managing Director Addresses to Shareholders  
 
    Successful Completion of A$7.5 Million Placement  
 
    Investor Update and Capital Raising - November 2013  
 
    Trading Halt  
 
    Appendix 4C - Quarter Ended 30 September 2013  
 
    QRxPharma Extends MOXDUO License with Aspen  
 
    Notice of 2013 Annual General Meeting and Proxy Form  
 
    QRxPharma reports Positive Meeting with the FDA on MOXDUO  
 
    Annual Report to Shareholders - 2013  
 
    2013 Annual General Meeting - Wednesday, 13 November 2013  
 
    QRxPharma Announces MOXDUO License with Aspen  
 
    FDA Schedules Review Meeting Regarding MOXDUO NDA  
 
    ASX/ Media Release - Preliminary Final Report 30 June 2013  
 
    Preliminary Final Report - 30 June 2013  
 
    CEO discusses Complete Response Letter on Open Briefing  
 
    Complete Response Letter from FDA regarding MOXDUO NDA  
 
    Trading Halt  
 
    Appendix 4C - Quarter Ended 30 June 2013  
 
    QRxPharma Announces Collaboration with Aesica  
 
    Change in substantial holding  
 
    CEO discusses MOXDUO NDA Review Update on Open Briefing  
 
    QRxPharma Updates MOXDUO NDA Review  
 
    Trading Halt  
 
    Appendix 3B - Exercise of Stock Options  
 
    QRxPharma Granted US Patent on Hybrid Opioids  
 
    Appendix 3B - Exercise of Stock Options  
 
    FDA sets 17 July 2013 for MOXDUO Advisory Committee Meeting  
 
    Appendix 3B - Exercise of Stock Options  
 
    Appendix 4C - Quarter Ended 31 March 2013  
 
    FDA sets 26 August 2013 as new PDUFA date for MOXDUO NDA  
 
    Investor Presentation Update - March 2013  
 
    QRxPharma Resubmits MOXDUO New Drug Application to the FDA  
 
    Appendix 3B - Option Issue  
 
    Investor Presentation Update - February 2013  
 
    Half Yearly Report and Accounts - 31 December 2012  
 
    Appendix 4C - Quarter Ended 31 December 2012  
 
    CEO discusses Path Forward for Resubmission of MOXDUO NDA  
 
    Path Forward For Resubmission of MOXDUO NDA  
 
    Appendix 3B - Exercise of Stock Options  
 
    Appendix 3B - Exercise of Stock Options  
 
    Investor Presentation Update - December 2012  
 
    Change in substantial holding  
 
    MAP Cancellation  
 
    Change in substantial holding  
 
    Ceasing to be a substantial holder  
 
    Change of Director's Interest Notice - Michael Quinn  
 
    Change of Director's Interest Notice - Gary Pace  
 
    Change of Director's Interest Notice - Peter Farrell  
 
    Change of Director's Interest Notice - Michael Quinn  
 
    Change of Director's Interest Notice - John Holaday  
 
    Appendix 3B - Option Issue  
 
    Change of Director's Interest Notice - Peter Campbell  
 
    Change of Director's Interest Notice - Peter Farrell  
 
    Change of Director's Interest Notice - Michael Quinn  
 
    Change of Director's Interest Notice - Gary Pace  
 
    Results of 2012 Annual General Meeting  
 
    Chairman and Managing Director Addresses to Shareholders  
 
    Appendix 4C - Quarter Ended 30 September 2012  
 
    Strategic Collaboration with Paladin Labs  
 
    Notice of 2012 Annual General Meeting and Proxy Form  
 
    Change in substantial holding  
 
    Annual Report to Shareholders - 2012  
 
    2012 Annual General Meeting - Wednesday, 7 November 2012  
 
    Investor Presentation Update - September 2012  
 
    Independent Audit Report - 30 June 2012  
 
    ASX/ Media Release - Preliminary Final Report 30 June 2012  
 
    Preliminary Final Report - 30 June 2012  
 
    CEO discusses Productive Meeting with FDA regarding MOXDUO  
 
    Productive Meeting With FDA Regarding MOXDUO NDA  
 
    Appendix 4C - Quarter Ended 30 June 2012  
 
    Change in substantial holding  
 
    Ceasing to be a substantial holder from BTT  
 
    Ceasing to be a substantial holder from WBC  
 
    CEO discusses Complete Response Letter from FDA  
 
    Complete Response Letter from FDA regarding MOXDUO NDA  
 
    Trading Halt  
 
    Ceasing to be a substantial holder  
 
    QRxPharma Granted Additional US Patent on MoxDuo  
 
    Appendix 3B - Exercise of Stock Options  
 
    US Commercialisation Partner Actavis to be acquired byWatson  
 
    Appendix 3B - Exercise of Stock Options  
 
    Appendix 3B - Option Issue  
 
    Appendix 4C - Quarter Ended 31 March 2012  
 
    Successful Completion of Phase 1 Studies for MoxDuo CR  
 
    Appendix 3B - Exercise of Stock Options  
 
    QRxPharma Signs License and Option Agreement with Actavis  
 
    Investor Presentation Update - March 2012  
 
    QRxPharma Presents at Cowen Health Care Live Audio Webcast  
 
    Appendix 3B - Exercise of Stock Options  
 
    Half Yearly Report and Accounts - 31 December 2011  
 
    Dr. Edward Rudnic Joins QRxPharma as Chief Operating Officer  
 
    Appendix 3B - Exercise of Stock Options  
 
    Appendix 4C - Quarter Ended 31 December 2011  
 
    Appendix 3B - Option Issue  
 
    Appendix 3B - Exercise of Stock Options  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Investor Presentation Update - January 2012  
 
    Change of Director`s Interest Notice - John Holaday  
 
    Change in substantial holding from BTT  
 
    Change of Interest from WBC  
 
    Appendix 3B - Exercise of Stock Options  
 
    QRxPharma CEO discusses Strategic Partnership with Actavis  
 
    QRxPharma Announces Strategic Partnership with Actavis  
 
    Trading Halt Request  
 
    Trading Halt  
 
    Change in substantial holding x 4  
 
    Change of Director`s Interest Notice - John Holaday  
 
    Appendix 3B - Option Issue  
 
    Results of 2011 Annual General Meeting  
 
    Chairman`s and Managing Director`s Addresses to Shareholders  
 
    PDUFA Target Date for FDA Action on MoxDuo IR NDA Granted  
 
    Appendix 3B - Exercise of Stock Options  
 
    Appendix 4C - Quarter Ended 30 September 2011  
 
    Appendix 3B - Option Issue  
 
    2011 Notice of Annual General Meeting and Proxy Form  
 
    Appendix 3B - Exercise of Stock Options  
 
    Annual Report to Shareholders - 2011  
 
    Change in substantial holding  
 
    Becoming a substantial holder  
 
    Change of Director`s Interest Notice - Peter Farrell  
 
    Change of Director`s Interest Notice - Gary Pace  
 
    Change of Director`s Interest Notice - Michael Quinn  
 
    Change of Director`s Interest Notice - Peter Campbell  
 
    Appendix 3B - Rights Issue  
 
    Non-renounceable Rights Issue Despatch of Holding Statements  
 
    QRxPharma Completes NDA Submission for MoxDuo IR  
 
    Non-renounceable Rights Issue Notice of under subscriptions  
 
    ASX/ Media Release - Preliminary Final Report 30 June 2011  
 
    Preliminary Final Report - 30 June 2011  
 
    Corporate Update and Rights Issue closing 22 August 2011  
 
    Change of Director`s Interest Notice - Michael Quinn  
 
    Correction Web Address - CEO discussion on Boardroom Radio  
 
    CEO on Recent Milestones and Rights Issue - Boardroom Radio  
 
    Notice of Despatch of Rights Issue Documents to Shareholders  
 
    Rights Issue - Notice to Ineligible Shareholders  
 
    Rights Issue - Letter to U.S. Eligible Shareholders  
 
    Appendix 3B - Exercise of Stock Options  
 
    Appendix 4C - Quarter Ended 30 June 2011  
 
    Notification Section 708A(5)(e) Corporations Act  
 
    QRxPharma Rights Issue - Entitlement and Acceptance Form  
 
    Non-Renounceable Rights Issue - Letter to Shareholders  
 
    Non-Renounceable Rights Issue - Letter to Option Holders  
 
    QRxPharma Rights Issue Booklet  
 
    Notification Section 708AA(2)(f) Corporations Act  
 
    Appendix 3B - Placement and Rights Issue  
 
    QRxPharma Announces A$35 Million Capital Raising  
 
    Investor Update and Capital Raising - 20 July 2011  
 
    Trading Halt  
 
    QRxPharma Announces NDA Filing for MoxDuo IR  
 
    Appendix 3B - Option Issue  
 
    Additional Data on MoxDuo IR Comparative Safety Study  
 
    Investor Presentation Update - June 2011  
 
    CEO discusses Comparative Safety Study on Boardroom Radio  
 
    Successful Completion MoxDuo IR Comparative Safety Study  
 
    Presentation of Clinical Data on MoxDuoTrials at APS Meeting  
 
    Appendix 3B - Exercise of Stock Options  
 
    Appendix 4C - Quarterly Report 31 March 2011  
 
    Enrolment of MoxDuo IR Comparative Safety Study Completed  
 
    USPTO Issues QRxPharma a New Patent for MoxDuo IR  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    QRxPharma on Track to File New Drug Application Mid-Year  
 
    Ceasing to be a substantial holder  
 
    Half Yearly Report and Accounts -31 December 2010  
 
    Investor Presentation Update - February 2011  
 
    Successful Completion Third Pivotal MoxDuo IR Phase 3  
 
    Appendix 4C - 31 December 2010  
 
    Initiation of Phase 3 Comparative Safety Study of MoxDuo IR  
 
    Appendix 3B - Option Issue  
 
    QRxPharma Securities Trading Policy  
 
    Enrolment of Pivotal MoxDuo IR Phase 3 Study Completed  
 
    Change of Director`s Interest Notice - Peter Campbell  
 
    Change of Director`s Interest Notice - Michael Quinn  
 
    Appendix 3B - Share Purchase Plan  
 
    $5.8 million SPP completes capital raising of $19.8 million  
 
    Change of Director`s Interest Notice - Michael Quinn  
 
    Change of Director`s Interest Notice - Gary Pace  
 
    Change of Director`s Interest Notice - Peter Campbell  
 
    Change of Director`s Interest Notice - John Holaday  
 
    Change of Director`s Interest Notice - Peter Farrell  
 
    Change in substantial holding  
 
    Appendix 3B - Option Issue  
 
    Notification Section 708A(5)(e) Corporations Act 2001 (Cth)  
 
    Appendix 3B - 2nd Tranche of Placement Issue  
 
    Amended Company Constitution 8 November 2010  
 
    Results of 2010 Annual General Meeting  
 
    Chairman`s and Managing Directors` Addresses to Shareholders  
 
    Additional U.S.Therapeutic Discovery Project Grant Awarded  
 
    Appendix 3B - Exercise of Stock Options  
 
    MoxDuo Awarded U.S. Therapeutic Discovery Project Grants  
 
    Appendix 3B - Option Issue  
 
    Appendix 4C -30 September 2010  
 
    Becoming a substantial holder  
 
    Share Purchase Plan_Opens 18 October 2010  
 
    2010 Annual Report to Shareholders - Printed and Web Copy  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Notification Section 708A(5)(e) Corporations Act 2001 (Cth)  
 
    Appendix 3B - Placement Issue announced 1 October 2010  
 
    Appendix 3B - Option Issue  
 
    Placement and Share Purchase Plan Listing Rule 3.10.3 Notice  
 
    A$14 Million Placement together with a Share Purchase Plan  
 
    Investor Update and Capital Raising - 29 September 2010  
 
    Annual Report to shareholders - 2010  
 
    Trading Halt  
 
    Appendix 3B - Option Issue  
 
    Interim Analysis of Final Pivotal Phase 3 Study MoxDuoIR  
 
    ASX/ Media Release - Preliminary Final Report 30 June 2010  
 
    Preliminary Final Report - 30 June 2010  
 
    MoxDuo IR recognised for innovation in pain therapy  
 
    Positive Phase 2 Proof of Concept Data for MoxDuoIV  
 
    Investor Presentation Update July 2010  
 
    Positive Scientific Advice Meetings in Europe MoxDou IR  
 
    Appendix 4C - 30 June 2010  
 
    Appendix 3B - Option Issue  
 
    Appendix 3B- - Exercise of Stock Options  
 
    Appendix 3B - Exercise of Stock Options  
 
    Ceasing to be a substantial holder  
 
    Phase 1 PK Study for MoxDuoCR Tablet Formula Successful  
 
    Response to ASX Query - Appendix 4C  
 
    Investor Presentation Update May 2010  
 
    Phase 3 Combination Rule Study for MoxDuo IR Additional Data  
 
    Appendix 4C - Quarterly Report 31 March 2010  
 
    Appendix 3B - Exercise of Stock Options  
 
    Phase 3 Combination Rule Study for MoxDuoIR Successful  
 
    Becoming a substantial holder  
 
    Ceasing to be a substantial holder  
 
    Appendix 3B - Exercise of Stock Options  
 
    Appendix 3B - Option Issue  
 
    Phase 1 Trial of Controlled-Release Dual-Opioid Initiated  
 
    Appendix 3B - Exercise of Stock Options  
 
    Change in substantial holding  
 
    Appendix 3B - Exercise of Stock Options  
 
    Strategic Alliance for Development of MoxDuo IV  
 
    Appendix 3B - Option Issue  
 
    Half Yearly Report and Accounts - 31 December 2009  
 
    QRxPharma Initiates Second Pivotal Phase 3 Study MoxDuoIR  
 
    Appendix 4C - Quarterly Report 31 December 2009  
 
    Change in substantial holding - John Holaday  
 
    Becoming a substantial holder - John Holaday  
 
    Appendix 3B - Option Issue  
 
    Becoming a substantial holder  
 
    Change in substantial holding from BTT  
 
    Change in substantial holding from WBC  
 
    Change of Director`s Interest Notice - Gary Pace  
 
    Change of Director`s Interest Notice - John Holaday  
 
    Change of Director`s Interest Notice - Michael Quinn  
 
    Change of Director`s Interest Notice - Peter Farrell  
 
    Change of Director`s Interest Notice - Peter Campbell  
 
    Appendix 3B - Rights Issue  
 
    Change in substantial holding  
 
    Rights Issue - Notice of Despatch of Shareholder Statements  
 
    Appendix 3B - Rights Issue  
 
    Notice of Subscriptions under Rights Issue  
 
    Change of Director`s Interest Notice - Michael Quinn  
 
    Change of Director`s Interest Notice - Michael Quinn  
 
    Change of Director`s Interest Notice - Gary Pace  
 
    Change of Director`s Interest Notice - John Holaday  
 
    Corporate Update and Rights Issue closing 15 December 2009  
 
    QRxPharma Initiates Pivotal Phase 3 Study of MoxDuoIR  
 
    Notice of Despatch of Rights Issue Documents to Shareholders  
 
    Rights Issue - Notice to Ineligible Shareholders  
 
    Rights Issue - Letter to U.S. Eligible Shareholders  
 
    Change of Director`s Interest Notice - John Holaday  
 
    Appendix 3B - Option Issue  
 
    Becoming a substantial holder  
 
    Appendix 3B - Placement Issue announced on 16 November 2009  
 
    Results of 2009 Annual General Meeting  
 
    Chairman`s and Managing Directors` Addresses to Shareholders  
 
    Reinstatement to Official Quotation  
 
    Renounceable Rights Issue - Letter to Shareholders  
 
    Renounceable Rights Issue - Letter to Option holders  
 
    Notification Section 708AA(2)(f) Corporations Act 2001 (Cth)  
 
    Appendix 3B - Placement and Rights Issue  
 
    Renounceable Rights Issue - Entitlement and Acceptance Form  
 
    QRxPharma Renounceable Rights Issue Booklet  
 
    A$21.6 Million Fully Underwritten Placement and Rights Issue  
 
    Investor Update and Capital Raising 13 November 2009  
 
    Suspension from Official Quotation  
 
    QRxPharma Investor Update and Capital Raising  
 
    Trading Halt  
 
    Appendix 4C - Quarterly Report 30 September 2009  
 
    Completion of Strategic Alliance Deal for Venomics Assets  
 
    Deal inked with Patheon for the Manufacture of MoxDou CR  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 3B - Option Issue  
 
    Ceasing to be a substantial holder  
 
    Annual Report to Shareholders - 2009  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Strategic Alliance for the Development of Venomics Assets  
 
    Appendix 3B - Option Issues  
 
    Corporate Presentation Update August 2009  
 
    MoxDuoIR Demonstrates Fewer Side Effects than Percocet  
 
    ASX/ Media Release - Preliminary Final Report 30 June 2009  
 
    Preliminary Final Report - 30 June 2009  
 
    Response to ASX Query - Change of Director`s Interest  
 
    Appendix 4C - Quarterly Report 30 June 2009  
 
    QRxPharma Initiates Comparative Phase 2 Sudy for MoxDuo IV  
 
    Change of Director`s Interest Notice - Michael Quinn  
 
    Appendix 3B - Release of Shares from ASX Restriction  
 
    Release of Shares from Voluntary Escrow and ASX Restriction  
 
    Corporate Presentation Update April 2009  
 
    Appendix 4C - Quarterly Report 31 March 2009  
 
    Successful Completion of Comparative Study for MoxDuoIR  
 
    Appendix 3B - Option Issues  
 
    Change of Director`s Interest Notice - Peter Farrell  
 
    Half Yearly Report and Accounts 31 December 2008  
 
    QRxPharma Initiates Second Comparative Study for MoxDuo IR  
 
    Change in substantial holding  
 
    Appendix 4C - Quarterly Report December 2008  
 
    Dr Jesus Soriano as Executive Vice President  
 
    QRxPharma Initiates Comparative Study for MoxDuoIR  
 
    Change in substantial holding  
 
    Becoming a substantial holder  
 
    Results of 2008 Annual General Meeting  
 
    Chairman`s and CEO`s Address to Shareholders  
 
    Appendix 4C - Quarter Ended 30 September 2008  
 
    Annual Report to Shareholders - 2008  
 
    Notice of Annual General Meeting/Proxy Form  
 
    ASX/ Media Release - Preliminary Final Report 30 June 2008  
 
    Preliminary Final Report - 30 June 2008  
 
    Change of Director`s Interest Notice - Peter Farrell  
 
    FDA Accepts Streamlined Phase 3 Development Plan Q8003IR  
 
    Appendix 4C - 30 June 2008  
 
    Change of Director`s Interest Notice - Michael Quinn  
 
    QRxPharma Begins Trading on the International OTCQX  
 
    Change of Director`s Interest Notice - Peter Campbell  
 
    Change of Director`s Interest Notice - John Holaday  
 
    Change of Director`s Interest Notice - Peter Farrell  
 
    QRxPharma Corporate Presentation - June 2008  
 
    QRxPharma Launches ADR Program  
 
    Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy  
 
    Appendix 3B - Release of Shares from Restriction and Escrow  
 
    Initial Phase 3 Study Results Dual Opioid Pain Therapy  
 
    Corporate Presentation Update May 2008  
 
    Appendix 4C - quarterly  
 
    Appendix 3B - Option Issues  
 
    Half Yearly Report and Accounts  
 
    Company Secretary Appointment/Resignation  
 
    Appendix 4C - Quarterly 31 December 2007  
 
    QRxPharma Reports Feedback from the FDA - Q8003IR  
 
    Change of Director`s Interest Notice - Gary Pace  
 
    Change of Director`s Interest Notice - Gary Pace  
 
    Ceasing to be a substantial holder  
 
    QRxPharma Initiates Second Phase III Clinical Trial  
 
    Change of Director`s Interest Notice - Micahel Quinn  
 
    Change of Director`s Interest Notice - Michael Quinn  
 
    Change of Director`s Interest Notice - Peter Farrell  
 
    Details of Company Address  
 
    Quotation of Securities  
 
    QRxPharma Enrolls First Patients in Phase III Clinical Trial  
 
    Change of Director`s Interest Notice - John Holaday  
 
    Results of Meeting  
 
    Chairman`s Address to Shareholders  
 
    QRxPharma Limited - Investor Update October 2007  
 
    Change in substantial holding from WBC  
 
    Appendix 4C - quarterly  
 
    Annual Report to shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Company Presentation Preliminary Final Report  
 
    ASX/ Media Release - Preliminary Final Report  
 
    Preliminary Final Report  
 
    Becoming a substantial holder from WBC  
 
    Ceasing to be a substantial holder from WBC  
 
    Initial Substantial Shareholder Notice from WBC  
 
    Appendix 4C - quarterly  
 
    Release of Shares from Escrow  
 
    Change of Director's Interest Notice  
 
    Becoming a substantial holder  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    QRxPharma Limited completes IPO/Trading commences on ASX  
 
    Pre-Quotation Disclosure  
 
    Top 20 shareholders  
 
    Distribution Schedule  
 
    Admission to Official List  
 
    ASX Circular: Commencement of Official Quotation  
 
    Constitution  
 
    Pre-quotation Disclosure re Shares and Options  
 
    Financial Statements 31 December 2006  
 
    Financial Statements 30 June 2006  
 
    Financial Statements 30 June 2005  
 
    Financial Statements 30 June 2004  
 
    Corporate Governance Statement  
 
    Full terms & conditions of ESOP  
 
    Appendix 1A: ASX Listing application and agreement  
 
    Disclosure Document